Gallant Therapeutics

Gallant Therapeutics

Biotechnology, SAN DIEGO, California, 92037, United States, 11-50 Employees

gallanttherapeutics.com

  • LinkedIn

phone no Phone Number: +12*********

Who is GALLANT THERAPEUTICS

Gallant Therapeutics is a clinical-stage animal health biotechnology company setting a new standard in animal health by harnessing the power of stem cell therapy to treat the root cause o...

Read More

map
  • SAN DIEGO, California, 92037, United States Headquarters: SAN DIEGO, California, 92037, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 5169; 6531

checked-icon Does something look wrong? Fix it. | View contact records from GALLANT THERAPEUTICS

Gallant Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Gallant Therapeutics

Answer: Gallant Therapeutics's headquarters are located at SAN DIEGO, California, 92037, United States

Answer: Gallant Therapeutics's phone number is +12*********

Answer: Gallant Therapeutics's official website is https://gallanttherapeutics.com

Answer: Gallant Therapeutics's revenue is $1 Million to $5 Million

Answer: Gallant Therapeutics's SIC: 5169; 6531

Answer: Gallant Therapeutics has 11-50 employees

Answer: Gallant Therapeutics is in Biotechnology

Answer: Gallant Therapeutics contact info: Phone number: +12********* Website: https://gallanttherapeutics.com

Answer: Gallant Therapeutics is a clinical-stage animal health biotechnology company setting a new standard in animal health by harnessing the power of stem cell therapy to treat the root cause of diseases in dogs and cats. Our pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies has the potential to treat a broad range of diseases, including canine and feline osteoarthritis (OA), feline chronic kidney disease (CKD), and others. The first product based on our uterine-derived platform for feline chronic gingivostomatitis (FCGS), is on track for conditional approval by the FDA in 2025. United by a love of and commitment to animals, Gallants team includes industry pioneers in veterinary regenerative medicine with deep experience in cell therapy product development, manufacturing and commercialization.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access